Cargando…
Challenges and advances in clinical applications of mesenchymal stromal cells
Mesenchymal stromal cells (MSCs), also known as mesenchymal stem cells, have been intensely investigated for clinical applications within the last decades. However, the majority of registered clinical trials applying MSC therapy for diverse human diseases have fallen short of expectations, despite t...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880217/ https://www.ncbi.nlm.nih.gov/pubmed/33579329 http://dx.doi.org/10.1186/s13045-021-01037-x |
_version_ | 1783650667327389696 |
---|---|
author | Zhou, Tian Yuan, Zenan Weng, Jianyu Pei, Duanqing Du, Xin He, Chang Lai, Peilong |
author_facet | Zhou, Tian Yuan, Zenan Weng, Jianyu Pei, Duanqing Du, Xin He, Chang Lai, Peilong |
author_sort | Zhou, Tian |
collection | PubMed |
description | Mesenchymal stromal cells (MSCs), also known as mesenchymal stem cells, have been intensely investigated for clinical applications within the last decades. However, the majority of registered clinical trials applying MSC therapy for diverse human diseases have fallen short of expectations, despite the encouraging pre-clinical outcomes in varied animal disease models. This can be attributable to inconsistent criteria for MSCs identity across studies and their inherited heterogeneity. Nowadays, with the emergence of advanced biological techniques and substantial improvements in bio-engineered materials, strategies have been developed to overcome clinical challenges in MSC application. Here in this review, we will discuss the major challenges of MSC therapies in clinical application, the factors impacting the diversity of MSCs, the potential approaches that modify MSC products with the highest therapeutic potential, and finally the usage of MSCs for COVID-19 pandemic disease. |
format | Online Article Text |
id | pubmed-7880217 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-78802172021-02-16 Challenges and advances in clinical applications of mesenchymal stromal cells Zhou, Tian Yuan, Zenan Weng, Jianyu Pei, Duanqing Du, Xin He, Chang Lai, Peilong J Hematol Oncol Review Mesenchymal stromal cells (MSCs), also known as mesenchymal stem cells, have been intensely investigated for clinical applications within the last decades. However, the majority of registered clinical trials applying MSC therapy for diverse human diseases have fallen short of expectations, despite the encouraging pre-clinical outcomes in varied animal disease models. This can be attributable to inconsistent criteria for MSCs identity across studies and their inherited heterogeneity. Nowadays, with the emergence of advanced biological techniques and substantial improvements in bio-engineered materials, strategies have been developed to overcome clinical challenges in MSC application. Here in this review, we will discuss the major challenges of MSC therapies in clinical application, the factors impacting the diversity of MSCs, the potential approaches that modify MSC products with the highest therapeutic potential, and finally the usage of MSCs for COVID-19 pandemic disease. BioMed Central 2021-02-12 /pmc/articles/PMC7880217/ /pubmed/33579329 http://dx.doi.org/10.1186/s13045-021-01037-x Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Zhou, Tian Yuan, Zenan Weng, Jianyu Pei, Duanqing Du, Xin He, Chang Lai, Peilong Challenges and advances in clinical applications of mesenchymal stromal cells |
title | Challenges and advances in clinical applications of mesenchymal stromal cells |
title_full | Challenges and advances in clinical applications of mesenchymal stromal cells |
title_fullStr | Challenges and advances in clinical applications of mesenchymal stromal cells |
title_full_unstemmed | Challenges and advances in clinical applications of mesenchymal stromal cells |
title_short | Challenges and advances in clinical applications of mesenchymal stromal cells |
title_sort | challenges and advances in clinical applications of mesenchymal stromal cells |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880217/ https://www.ncbi.nlm.nih.gov/pubmed/33579329 http://dx.doi.org/10.1186/s13045-021-01037-x |
work_keys_str_mv | AT zhoutian challengesandadvancesinclinicalapplicationsofmesenchymalstromalcells AT yuanzenan challengesandadvancesinclinicalapplicationsofmesenchymalstromalcells AT wengjianyu challengesandadvancesinclinicalapplicationsofmesenchymalstromalcells AT peiduanqing challengesandadvancesinclinicalapplicationsofmesenchymalstromalcells AT duxin challengesandadvancesinclinicalapplicationsofmesenchymalstromalcells AT hechang challengesandadvancesinclinicalapplicationsofmesenchymalstromalcells AT laipeilong challengesandadvancesinclinicalapplicationsofmesenchymalstromalcells |